The present study is conducted in order to assess the acceptability of Hepatitis B vaccination in French general population before and after reimbursement of the paediatric vaccine InfanrixHexa. Four measurements are planned, first before reimbursement and the others at year 1, 2 and 3 after reimbursement.

The present study aims to evaluate the changes in Hepatitis B immunization coverage and the acceptability thereof among parents, in the general population. This is a national, prospective, epidemiological study, comprising four measurement time-points over a three-year period, (T1 in 2009, T2 in 2010, T3 in 2011, and T4 in 2012) in order to cover the period prior to the introduction of InfanrixHexa® reimbursement, the transition period, and the period following reimbursement of the vaccine. The periods between each data collection time-point will be identical, lasting a year. Two age groups will be investigated at each data collection time-point: 12-15 months and 24-27 months, thus providing measurements before/after reimbursement.

Inclusion Criteria:

• Infants aged 12 to 15 months or 24 to 27 months inclusive at the time of the study.
• With a parent or legal representative agreeing to take part in the interview.
• Residing in metropolitan France.

Exclusion Criteria:

• Refusal to take part.
• Infants having lived in another country in their first two years of life.

The study population will consist of parents (with infants) agreeing to take part in a personal interview.